Metabolic Dysfunction and Male Pelvic Health

European Urology

Volumn 52, Issue 2, 2007, Pages 316-317

  Kaplan, Steven A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR;

DISEASE ASSOCIATION; EDITORIAL; ERECTILE DYSFUNCTION; HUMAN; HYPERINSULINEMIA; LOWER URINARY TRACT SYMPTOM; METABOLIC DISORDER; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION;

HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; PROSTATIC HYPERPLASIA; PYRROLES; URINATION DISORDERS;

EID: 34250756063     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.080     Document Type: Editorial

References (5)

1. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
2. Parsons J.K., Carter H.B., Partin A.W., et al. Metabolic factors associated with benign hyperplasia. J Clin Endocrinol Metab 91 (2006) 2562-2568
3. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 Suppl 2 (2006) 23-28
4. Nandeesha H., Koner B.C., Dorairajan L.N., and Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 370 (2006) 89-93
5. Mills I.W., Crossland A., Patel A., and Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostate enlargement. Eur Urol. 52 (2007) 503-509